¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"IMM"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • immunogen RNA
    ¸é¿ª¿øRNA
  • immunogenetic
    ¸é¿ªÀ¯Àü-
  • immunogenetics
    ¸é¿ªÀ¯ÀüÇÐ
  • immunogenic
    ¸é¿ª¿ø-
  • immunogenic determinant
    ¸é¿ª¿ø°áÁ¤ÀÎÀÚ
  • immunogenicity
    ¸é¿ª¿ø¼º
  • immunoglobulin
    ¸é¿ª±Û·ÎºÒ¸°
  • immunoglobulin A
    ¸é¿ª±Û·ÎºÒ¸°A
  • immunoglobulin adhesion receptor
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂø¼ö¿ëü
  • immunoglobulin class
    ¸é¿ª±Û·ÎºÒ¸°°è
  • immunoglobulin cleavage
    ¸é¿ª±Û·ÎºÒ¸°ºÐÇÒ
  • immunoglobulin D
    ¸é¿ª±Û·ÎºÒ¸°D
  • immunoglobulin domain
    ¸é¿ª±Û·ÎºÒ¸°¿µ¿ª
  • immunoglobulin E
    ¸é¿ª±Û·ÎºÒ¸°E
  • immunoglobulin G
    ¸é¿ª±Û·ÎºÒ¸°G
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • immunofluorescence antibody
    ¸é¿ªÇü±¤Ç×ü
  • immunofluorescence assay
    ¸é¿ªÇü±¤ÃøÁ¤
  • immunofluorescence microscopy
    ¸é¿ªÇü±¤Çö¹Ì°æ°Ë»ç¹ý
  • immunofluorescent test
    ¸é¿ªÇü±¤°Ë»ç
  • immunogen
    ¸é¿ª¿ø
  • immunogen RNA
    ¸é¿ª¿ø¼º¾Ë¿£¿¡ÀÌ
  • immunogenetic
    ¸é¿ªÀ¯Àü-
  • immunogenetics
    ¸é¿ªÀ¯ÀüÇÐ
  • immunogenic
    ¸é¿ª¿ø¼º-
  • immunogenic determinant
    ¸é¿ª¿ø°áÁ¤±â
  • immunogenicity
    ¸é¿ª¿ø¼º
  • immunoglobulin
    ¸é¿ª±Û·ÎºÒ¸°
  • immunoglobulin adhesion receptor
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂø¼ö¿ëü
  • immunoglobulin class
    ¸é¿ª±Û·ÎºÒ¸°°è
  • immunoglobulin cleavage
    ¸é¿ª±Û·ÎºÒ¸°ºÐÇÒ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • immune selection
    ¸é¿ª¼±ÅÃ
  • immune serum
    ¸é¿ªÇ÷û.
  • immune serum globulin
    ¸é¿ª Ç÷û ±Û·ÎºÒ¸°
  • immune serum globulin
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°.
  • immune serum globulin transfusion
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°¼öÇ÷
  • immune state
    ¸é¿ª»óÅÂ
  • immune surveillance
    ¸é¿ª°¨½Ã
  • immune surveillance
    ¸é¿ª[ÇÐÀû]°¨½Ã±âÀü
  • Immune system
    ¸é¿ªÃ¼°è(Øóæ¹ô÷ͧ)
  • immune system
    ¸é¿ª°è.
  • immune system
    ¸é¿ª°è(Øóæ¹Í§)
  • immune thrombocytopenia
    ¸é¿ªÇ÷¼ÒÆÇ°áÇÌÁõ
  • immune tolerance
    ¸é¿ª°ü¿ë
  • immune-electron microscopy
    ¸é¿ªÀüÀÚÇö¹Ì°æ¹ý
  • immune-mediated hemolysis
    ¸é¿ª¸Å°³¼º ¿ëÇ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • immune precipitate
    ¸é¿ªÄ§°­¹°
  • immune protein
    ¸é¿ª´Ü¹éÁú.
  • immune reaction
    ¸é¿ª¹ÝÀÀ.
  • immune reactivity
    ¸é¿ª¹ÝÀÀ¼º.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immune ring
    ¸é¿ª°í¸®, ¸é¿ª·û
  • immune selection
    ¸é¿ª¼±ÅÃ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
immunization, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
immunization, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
immunization, hib This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
immunization, infectious hepatitis See Immunization, hepatitis a.
(12 Dec 1998)
immunization, influenza See Immunization, flu.
(12 Dec 1998)
immunization, measles See Immunization, MMR.
(12 Dec 1998)
immunization, mmr The standard vaccine given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most u.s. Colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
immunization, mumps See Immunization, MMR.
(12 Dec 1998)
immunization, passive Transfer of immunity from immunised to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (adoptive transfer).
(12 Dec 1998)
immunization, pneumococcal pneumonia This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
immunization, polio The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine). Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth. Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age. Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(12 Dec 1998)
immunization, rubella See Immunization, MMR.
(12 Dec 1998)
immunization, secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
(12 Dec 1998)
immunization, serum hepatitis See Immunization, hepatitis b.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 5 ÆäÀÌÁö: 9
  • Immunoglobulin A, Secretory - »õâ The principle immunoglobulin in exocrine secretions such as milk, respiratory and intestinal mucin, saliva and tears. The complete molecule (around 400 kD) is composed of two four-chain units of IMMUNOGLOBULIN A, one SECRETORY COMPONENT and one J chain (IMMUNOGLOBULIN J-CHAINS).
    Synonyms : Secretory Immunoglobulin A, Exocrine IgA, IgA, Colostral
  • Immunoglobulin Allotypes - »õâ Allelic variants of the immunoglobulin light chains (IMMUNOGLOBULIN LIGHT CHAINS) or heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) encoded by ALLELES of IMMUNOGLOBULIN GENES.
    Synonyms : Ig Allotypes, Allotype, Ig, Allotype, Immunoglobulin, Allotypes, Ig, Allotypic Antibody, Antibody, Allotypic, Ig Allotype, Immunoglobulin Allotype
  • Immunoglobulin alpha-Chains - »õâ The class of heavy chains found in IMMUNOGLOBULIN A. They have a molecular weight of approximately 58 kDa and contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to their Fc fragment constant region.
    Synonyms : Immunoglobulin alpha-Chain, alpha-Chain Immunoglobulins, alpha-Immunoglobulin Heavy Chain, alpha-Immunoglobulin Heavy Chains, Heavy Chain, alpha-Immunoglobulin, Heavy Chains, alpha-Immunoglobulin, Immunoglobulin alpha Chains, Immunoglobulins, alpha Chain
  • Immunoglobulin Class Switching - »õâ Gene rearrangement of the B-lymphocyte which results in a substitution in the type of heavy-chain constant region that is expressed. This allows the effector response to change while the antigen binding specificity (variable region) remains the same. The majority of class switching occurs by a DNA recombination event but it also can take place at the level of RNA processing.
    Synonyms : Class Switching, Immunoglobulin, Class Switchings, Class Switchings, Immunoglobulin, Immunoglobulin Class Switchings, Isotype Switchings, Switching, Class, Switching, Immunoglobulin Class, Switching, Isotype, Switchings, Class, Switchings, Immunoglobulin Class
  • Immunoglobulin Constant Regions - »õâ The domains of the immunoglobulin molecules that are invariable in their amino acid sequence within any class or subclass of immunoglobulin. They confer biological as well as structural functions to immunoglobulins. One each on both the light chains and the heavy chains comprises the C-terminus half of the IMMUNOGLOBULIN FAB FRAGMENT and two or three of them make up the rest of the heavy chains (all of the IMMUNOGLOBULIN FC FRAGMENT)
    Synonyms : Constant Region, Ig, Constant Region, Immunoglobulin, Constant Regions, Immunoglobulin
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 5 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
immunoelectrophoresis electrophoresis to separate antigens and antibodies
Ãâó: wordnet.princeton.edu/perl/webwn
immunofluorescence (immunology) a technique that uses antibodies linked to a fluorescent dye in order to study antigens in a sample of tissue
Ãâó: wordnet.princeton.edu/perl/webwn
immunogen any substance or organism that provokes an immune response (produces immunity) when introduced into the body
Ãâó: wordnet.princeton.edu/perl/webwn
immunohistochemistry an assay that shows specific antigens in tissues by the use of markers that are either fluorescent dyes or enzymes (such as horseradish peroxidase)
Ãâó: wordnet.princeton.edu/perl/webwn
immunogenic possessing the ability to elicit an immune response
Ãâó: wordnet.princeton.edu/perl/webwn
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • immovable
    ¿òÁ÷ÀÏ ¼ö ¾ø´Â
  • immovable
    ¿òÁ÷ÀÏ ¼ö ¾ø´Â;¿òÁ÷ÀÌÁö ¾Ê´Â;°íÁ¤µÈ;Á¤ÁöÇÑ;ºÎµ¿ÀÇ;È®°íÇÑ;Å¿¬;ÀÚ¾àÇÑ;°¨Á¤¿¡ Á¿ìµÇÁö ¾Ê´Â;¹«°¨µ¿ÀÇ ³ÃÁ¤ÇÑ;(ÃàÁ¦ÀÏ,±â³äÀϵîÀÌ)ÇØ¸¶´Ù °°Àº ³¯Â¥ÀÇ °íÁ¤µÈ;(¹ý)(Àç»êÀÌ)ºÎµ¿ÀÇ;(¹ý)ºÎµ¿»ê
  • immovablly
  • immovablness
  • immune
    ¸é¿ªÀÇ
  • immune
    ¸é¿ªÀÇ;(Àü¿°º´,º´µ¶µîÀ»)¸éÇÑ;¸é¿ª¼ºÀÇ(to,from);(°ú¼¼,°ø°Ý µî¿¡¼­);¸éÁ¦µÈ(exempt);(..À») ´çÇÒ ¿°·Á°¡ ¾ø´Â(from,against);(¿¡)µ¿ÇÏÁö ¾Ê´Â;¿µÇâÀ» ¹ÞÁö ¾Ê´Â(to);¸é¿ª(¸éÁ¦)ÀÚ
  • immune body
    ¸é¿ªÃ¼;Ç×ü(antibody)
  • immune complex
    ¸é¿ª º¹ÇÕü
  • immune response
    ¸é¿ª ÀÀ´ä;¸é¿ª ¹ÝÀÀ
  • immune serum
    ¸é¿ª Ç÷û
  • immune surveillance
    IMMUNOLOGICAL SURVEILLANCE
  • immunity
    ¸é¿ª
  • immunity
    (Ã¥ÀÓ,Àǹ«µîÀÇ)¸éÁ¦;ƯÀü;(Àü¿°º´ µî¿¡ ´ëÇÑ)¸é¿ª¼º;¸é¿ªÁú;(±³È¸ÀÇ ¼¼¼ÓÀû Àǹ«ÀÇ)¸éÁ¦
  • immunity bath
    ¸éÃ¥;Ư±Ç;±â¼Ò(¼ÒÃß)¸éÁ¦;(Áõ¾ðÀ» ¾ò±â À§ÇØ ÁõÀο¡ ´ëÇÑ ±â¼Ò¸¦ ¸éÁ¦ÇÔ
  • immunization
    ¸é¿ª(¹ý);¸é¿ªÁ¶Ä¡;¸éÁ¦;(¸é¿ª)¿¹¹æÁÖ»ç
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 12 ÆäÀÌÁö: 9
IMM fixation (as by a plaster cast) of a body part in order to promote proper healing
IMM cause to be unable to move
IMM prohibit the conversion or use of (assets)
IMM convert (assets) into fixed capital
IMM make defenseless
IMM to hold fast or prevent from moving
IMM hold as reserve or withdraw from circulation
IMM the act of limiting movement or making incapable of movement
IMM not within reasonable limits
IMM to a degree that exceeds the bounds or reason or moderation
IMM in an immoderate manner
IMM the quality of being excessive and lacking in moderation
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 5 ÆäÀÌÁö: 9
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á